Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 07, 2024

SELL
$27.21 - $39.48 $11,809 - $17,134
-434 Reduced 5.07%
8,125 $232,000
Q4 2023

Feb 09, 2024

SELL
$21.2 - $31.03 $6,911 - $10,115
-326 Reduced 3.67%
8,559 $261,000
Q3 2023

Nov 02, 2023

SELL
$26.2 - $36.08 $3,275 - $4,510
-125 Reduced 1.39%
8,885 $238,000
Q2 2023

Aug 08, 2023

SELL
$25.16 - $41.38 $12,026 - $19,779
-478 Reduced 5.04%
9,010 $321,000
Q4 2022

Feb 08, 2023

BUY
$28.0 - $40.56 $3,864 - $5,597
138 Added 1.48%
9,488 $0
Q3 2022

Nov 10, 2022

BUY
$29.63 - $48.31 $37,244 - $60,725
1,257 Added 15.53%
9,350 $309 Million
Q2 2022

Aug 05, 2022

SELL
$27.79 - $50.61 $3,056 - $5,567
-110 Reduced 1.34%
8,093 $285,000
Q1 2022

May 04, 2022

BUY
$39.62 - $69.97 $32,012 - $56,535
808 Added 10.93%
8,203 $377,000
Q4 2021

Feb 02, 2022

BUY
$58.09 - $82.51 $55,301 - $78,549
952 Added 14.78%
7,395 $490,000
Q3 2021

Nov 10, 2021

BUY
$58.38 - $84.96 $57,621 - $83,855
987 Added 18.09%
6,443 $402,000
Q2 2021

Aug 11, 2021

BUY
$62.15 - $90.32 $46,798 - $68,010
753 Added 16.01%
5,456 $452,000
Q1 2021

May 10, 2021

BUY
$61.35 - $90.47 $288,529 - $425,480
4,703 New
4,703 $312,000

Others Institutions Holding ARWR

About ARROWHEAD PHARMACEUTICALS, INC.


  • Ticker ARWR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 105,849,000
  • Market Cap $2.01B
  • Description
  • Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, w...
More about ARWR
Track This Portfolio

Track Pictet & Cie (Europe) Sa Portfolio

Follow Pictet & Cie (Europe) Sa and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Pictet & Cie (Europe) Sa, based on Form 13F filings with the SEC.

News

Stay updated on Pictet & Cie (Europe) Sa with notifications on news.